10X Genomics Inc Class A (TXG) financials
10X Genomics revenue and earnings by year
10X Genomics's revenue was $643 million in the fiscal year to December 31, 2025, up 5.2% from the year before. Net income was -$43.5 million, -6.8% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 31.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 643 | 611 | 619 | 516 | 490 | 299 | 246 | 146 | 71 |
| Revenue growth | 5.2% | -1.3% | 19.8% | 5.3% | 64.1% | 21.5% | 68.1% | 105.8% | — |
| Gross profit | 444 | 414 | 409 | 396 | 416 | 240 | 185 | 118 | 61 |
| Gross margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating income | -61 | -195 | -265 | -168 | -52 | -534 | -31 | -111 | -18 |
| Operating margin | -9.5% | -31.9% | -42.9% | -32.5% | -10.7% | -178.7% | -12.4% | -75.7% | -25.8% |
| Net income | -44 | -183 | -255 | -166 | -58 | -543 | -31 | -112 | -19 |
| Net margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
| Diluted EPS | -$0.35 | -$1.52 | -$2.18 | -$1.46 | -$0.53 | -$5.37 | — | — | — |
| Free cash flow | 130 | -6 | -64 | -165 | -123 | -255 | -8 | -83 | -14 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TXG in Markets.
How 10X Genomics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Chromium Consumables | $88.5M | 58.6% |
| Spatial Consumables | $42.3M | 28.0% |
| Services | $10.7M | 7.1% |
| Spatial Instruments | $4.57M | 3.0% |
| Chromium Instruments | $3.09M | 2.0% |
| Licensing & Royalty Revenue | $1.94M | 1.3% |
See also: TXG returns
No forecast, no recommendation. This page describes 10X Genomics Inc Class A from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.